Answer
Cell-based Trivalent Influenza Vaccine Seqirus is indicated for influenza prevention in adults and children from 6 months of age and should be used in accordance with official recommendations.
Sources for this answer
- Cell-based Trivalent Influenza Vaccine SeqirusSeqirus UK Limited · emc · SmPC §4.1 Therapeutic Indications · Version 3Document updated
Sources checked